Serotonergic drugs for depression and beyond

Current Drug Targets

Volumn 14, Issue 5, 2013, Pages 578-585

  Stahl, Stephen M ^a,b,c,d,e   Lee Zimmerman, Clara ^a   Cartwright, Sylvia ^a   Morrissette, Debbi Ann ^c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^d not available   (United Kingdom)

^e not available   (United States)

Author keywords

5HT1A; 5HT1B D; 5HT2A; 5HT2C; 5HT3; 5HT7; NET; SERT; SNRI; SSRI

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; CITALOPRAM; DESVENLAFAXINE; DOPAMINE; DOPAMINE TRANSPORTER; DULOXETINE; EDIVOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; NORADRENALIN TRANSPORTER; PAROXETINE; QUETIAPINE; SEROTONIN AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SERTRALINE; TRAZODONE; VENLAFAXINE; VILAZODONE;

ARTICLE; BIPOLAR DEPRESSION; CLINICAL TRIAL (TOPIC); DEPRESSION; HUMAN; NERVE ENDING; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; SEROTONINERGIC NERVE CELL;

EID: 84876738342     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314050007     Document Type: Article

References (69)

1. Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. Br J Gen Pract 2011; 61(590): e565-72.
2. Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 2011; 13(4): 423-37.
3. Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008; 111(5): 1175-82.
4. Stahl SM. Stahl's Essential Psychopharmacology. 4th ed. New York: Cambridge University Press; 2013.
5. Ni YG, Miledi R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 1997; 94(5): 2036-40.
6. Tang SW, Helmeste D. Paroxetine. Expert Opin Pharmacother 2008; 9(5): 787-94.
7. Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 2008; 6(4): 344-66.
8. Zhong H, Haddjeri N, Sanchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 2012; 219(1): 1-13.
9. Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 2003; 64(2): 110-1.
10. Stahl SM. Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. J Clin Psychiatry 2003; 64(3): 230-1.
11. Stahl SM. Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry 2003; 64(1): 4-5.
12. Briley M, Moret C. Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr 2008; 13(7 Suppl 11): 22-6.
13. Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol 1996; 16(3 Suppl 2): 21S-6S; discussion 6S-8S.
14. Phelps NJ, Cates ME. The role of venlafaxine in the treatment of obsessive-compulsive disorder. Ann Pharmacother 2005; 39(1): 136-40.
15. Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder. Expert Rev Neurother 2007; 7(6): 603-15.
16. Pae CU. Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother 2011; 12(18): 2923-8.
17. Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 2008; 14(6): 368-78.
18. Monteleone F, Caputo M, Tecce MF, Capasso A. Duloxetine in the treatment of depression: an overview. Cent Nerv Syst Agents Med Chem 2011; 11(3): 174-83.
19. Bril V. Treatments for diabetic neuropathy. J Peripher Nerv Syst 2012; 17 Suppl 2:22-7.
20. Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012; 26(4): 297-307.
21. Citrome L, Weiss-Citrome A. A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Postgrad Med 2012; 124(1): 83-93.
22. Kasper S, Pail G. Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat 2010; 6: 23-31.
23. Bose A, Gommoll C, Li H, Rut A. Levominacipran in the treatment of major depressive disorer: an analysis of efficacy data from 2 pahse III studies. American Psychiatric Association Annual Meeting; May 8; Philadelphia, PA2012.
24. Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs 2011; 25(9): 803-13.
25. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012; 26(5): 435-60.
26. Pangallo B, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res 2011; 45(6): 748-55.
27. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006; 12(3-4): 178-207.
28. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002; 163(1): 102-5.
29. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004; 161(5): 826-35.
30. Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann N Y Acad Sci 2010; 1187: 316-40.
31. Fowler JS, Volkow ND, Wang GJ, Gatley SJ, Logan J. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001; 28(5): 561-72.
32. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56(9): 395-401.
33. Rush AJ. Star-D: lessons learned and future implications. Depress Anxiety 2011; 28(7): 521-4.
34. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905-17.
35. Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 2012; 125(4): 342-8.
36. Moreira R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Investig 2011; 31 Suppl 1: 5-17.
37. Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009; 10(11): 1069-84.
38. Prins J, Olivier B, Korte SM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin Investig Drugs 2011; 20(8): 1107-30.
39. Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 2006; 12(2): 123-34.
40. Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, doubleblind, placebo-controlled trial. J Psychiatr Res 2012; 46(1): 64-71.
41. Potter WZ. Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. J Clin Psychiatry 1996; 57 Suppl 4: 4-8.
42. Langer SZ. Presynaptic autoreceptors regulating transmitter release. Neurochem Int 2008; 52(1-2): 26-30.
43. Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011; 12(10): 1623-32.
44. Kim JE, Yoon SJ, Kim J, et al. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract 2011; 65(3): 323-9.
45. Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V. A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol 1997; 49(4): 403-11.
46. Dawson LA, Nguyen HQ. Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol 1998; 345(1): 41-6.
47. Singh M, Schwartz TL. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr Dis Treat 2012; 8: 123-30.
48. Bartoszyk GD, Hegenbart R, Ziegler H. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 1997; 322(2-3): 147-53.
49. Rabiner EA, Gunn RN, Wilkins MR, et al. Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl Med Biol 2000; 27(5): 509-13.
50. de Paulis T. Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs 2007; 10(3): 193-201.
51. Carvalho AF, Cavalcante JL, Castelo MS, Lima MC. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 2007; 32(5): 415-28.
52. Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 2009; 18(11): 1753-64.
53. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19(1): 67-85.
54. Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Therapeutic Advances in Psychopharmacology 2011; 1(3): 81-7.
55. Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4(4): 331-55.
56. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011; 24(1): 10-7.
57. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007; 113(2): 296-320.
58. Dodd S, Berk M. Olanzapine/fluoxetine combination for treatmentresistant depression: efficacy and clinical utility. Expert Rev Neurother 2008; 8(9): 1299-306.
59. Ravindran AV, Al-Subaie A, Abraham G. Quetiapine: novel uses in the treatment of depressive and anxiety disorders. Expert Opin Investig Drugs 2010; 19(10): 1187-204.
60. Stoner SC, Pace HA. Asenapine: a clinical review of a secondgeneration antipsychotic. Clin Ther 2012; 34(5): 1023-40.
61. Roberts C, Thomas DR, Bate ST, Kew JN. GABAergic modulation of 5-HT7 receptor-mediated effects on 5-HT efflux in the guineapig dorsal raphe nucleus. Neuropharmacology 2004; 46(7): 935-41.
62. Mnie-Filali O, Faure C, Lambas-Senas L, et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011; 36(6): 1275-88.
63. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012; 28(10): 1717-24.
64. Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012; 340(3): 666-75.
65. Pehrson AL, Cremers T, Betry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 2012.
66. Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2012: 1-9.
67. Moret C, Briley M. The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 2000; 404(1-2): 1-12.
68. Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J Psychopharmacol 2010; 24(4): 455-69.
69. Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 2012; 17(1): 105-26.